TUBA1B tubulin alpha 1b
ENSG00000123416 · protein coding · Open Targets profile
Tubulin is the major constituent of microtubules, protein filaments consisting of alpha- and beta-tubulin heterodimers (PubMed:38305685, PubMed:34996871, PubMed:38609661). Microtubules grow by the addition of GTP-tubulin dimers to the microtubule end, where a stabilizing cap forms (PubMed:38305685, PubMed:34996871, PubMed:38609661). Below the cap, tubulin dimers are in GDP-bound state, owing to GTPase activity of alpha-tubulin (PubMed:34996871, PubMed:38609661). {ECO:0000269|PubMed:34996871, ECO:0000269|PubMed:38305685, ECO:0000269|PubMed:38609661}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Approved Drug, Structure with Ligand, High-Quality Ligand, Druggable Family
- PROTAC
- UniProt Ubiquitination, Database Ubiquitination, Small Molecule Binder
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.029047999531030655 (upper bound 0.13779999315738678). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 400 registry trials, updated in the last three years, of the most advanced drugs against TUBA1B (vincristine, vinorelbine, ixabepilone, paclitaxel poliglumex, vinflunine, vinblastine, glembatumumab vedotin, mirvetuximab soravtansine, polatuzumab vedotin, cabazitaxel, trastuzumab emtansine, brentuximab vedotin), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Alex F HerreraCity of Hope Medical Center · 5 of 5 trials Phase 2+
- Elias JabbourM.D. Anderson Cancer Center · 4 of 4 trials Phase 2+Ph2NCT01424982 · Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemiabrief
- Ana AparicioM.D. Anderson Cancer Center · 3 of 3 trials Phase 2+Ph1/Ph2NCT06085729 · Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)brief
- Seth E. KarolSt. Jude Children's Research Hospital · 3 of 3 trials Phase 2+Ph1/Ph2NCT05192889 · Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclaxbrief
- Bristol-Myers SquibbBristol-Myers Squibb · 2 of 3 trials Phase 2+Ph2NCT06425302 · A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphomabrief
- Joseph M TuscanoCity of Hope Comprehensive Cancer Center LAO · 2 of 3 trials Phase 2+Ph1NCT06015880 · Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphomabrief
- Adrienne WaksDana-Farber Cancer Institute · 2 of 2 trials Phase 2+
- Alex HerreraCity of Hope Medical Center · 2 of 2 trials Phase 2+
- Alison MoskowitzMemorial Sloan Kettering Cancer Center · 2 of 2 trials Phase 2+
- Amar GajjarSt. Jude Children's Research Hospital · 2 of 2 trials Phase 2+
- Binghe XuOncology Hospital, Chinese Academy of Medical Sciences · 2 of 2 trials Phase 2+
- Carlos Rodriguez-GalindoNorth American Consortium for Histiocytosis · 2 of 2 trials Phase 2+
- Dai ChiharaUT MD Anderson Cancer Center · 2 of 2 trials Phase 2+
- David McCallM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Elena ParovichnikovaNational Research Center for Hematology · 2 of 2 trials Phase 2+
Registry trials of vincristine, vinorelbine, ixabepilone, paclitaxel poliglumex, vinflunine, vinblastine, glembatumumab vedotin, mirvetuximab soravtansine, polatuzumab vedotin, cabazitaxel, trastuzumab emtansine, brentuximab vedotin updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 250 of 383 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 17 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
383 trials of drugs against TUBA1B were stopped early; 16 of the 200 most recent give no reason
Terminated, withdrawn and suspended interventional trials of vincristine, vinorelbine, ixabepilone, paclitaxel poliglumex, vinflunine, vinblastine, glembatumumab vedotin, mirvetuximab soravtansine, polatuzumab vedotin, cabazitaxel, trastuzumab emtansine, brentuximab vedotin, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 383.
- terminated · 2026-10-15 · Spanish Breast Cancer Research Group · Vinorelbine“Study prematurely terminated due to recruitment challenges, low incidence of the target population, evolving treatment landscape, ethical considerations, and inability to ensure funding through study completion.”
- terminated · 2026-10-05 · Children's Oncology Group · Vincristine Sulfate“Drug supply issues”
- suspended · 2026-09-29 · University of Washington · Vincristine“Safety Review”
- withdrawn · 2026-09-24 · Case Comprehensive Cancer Center · matched by the registry's drug synonyms“PI left institution”
- terminated · 2026-09-21 · Institut Claudius Regaud · Zolinza (vorinostat), vinorelbineNo reason given
- terminated · 2026-09-18 · Pusan National University Yangsan Hospital · matched by the registry's drug synonyms“Poor accrual due to increased use of alternative neoadjuvant treatment options.”
- terminated · 2026-09-17 · Centre Oscar Lambret · Vinblastine“Analysis conducted on spring 2025, according to the provisional schedule: the results were sufficient to conclude about all endpoints, and the sponsor defined a new end of trial on 27 Dec 2025 (modification approved on CTIS on May 26, 2026).”
- suspended · 2026-09-01 · CStone Pharmaceuticals · Vincristine“The sponsor is temporarily pausing the trial to evaluate existing clinical data for long-term benefit-risk and optimize doses and dosing schedule.”
- terminated · 2026-08-20 · Jules Bordet Institute · Trastuzumab emtansine“Study logistics or limited study population, as defined by the iclusion/exclusion criteria, leading to a poor recruitment”
- terminated · 2026-07-30 · M.D. Anderson Cancer Center · Vincristine Sulfate“the study was closed early due to competing trials”
- suspended · 2026-06-15 · University of Alabama at Birmingham · Brentuximab vedotin“IRB audit”
- withdrawn · 2026-05-14 · Institute of Hematology & Blood Diseases Hospital, China · matched by the registry's drug synonyms“drug-associated adverse reactions”
- terminated · 2026-05-13 · M.D. Anderson Cancer Center · Vincristine“<75% participation”
- terminated · 2026-04-16 · UNC Lineberger Comprehensive Cancer Center · Polatuzumab vedotin (PV)“Funding”
- withdrawn · 2026-04-01 · Eric Jacobsen, MD · Vincristine“Ipsen requested a temporary closure due to a safety concern.”
- withdrawn · 2026-03-18 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Vincristine“Replaced with another clinical trial.”
- suspended · 2026-03-16 · National Cancer Institute (NCI) · Vincristine“Pending updated agreements in order to enroll additional participants.”
- terminated · 2026-03-12 · Allarity Therapeutics · Ixabepilone Injection“Company Decision”
- terminated · 2026-03-02 · BeiGene · matched by the registry's drug synonyms“Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.”
- terminated · 2026-01-06 · Fundacio Clinic Barcelona · matched by the registry's drug synonyms“The study was prematurely halted primarily due to low patient accrual. Despite efforts to optimize recruitment, the enrollment rate remained insufficient to meet the predefined targets, and continuation was deemed unfeasible”
- terminated · 2025-12-16 · Mario Negri Institute for Pharmacological Research · durvalumab plus platinum-based chemotherapy (cisplatin or carboplatin plus vinorelbine or pemetrexed)“Low enrolment rate”
- terminated · 2025-12-10 · Spanish Breast Cancer Research Group · Vinorelbine“The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.”
- terminated · 2025-10-23 · European Organisation for Research and Treatment of Cancer - EORTC · Vincristine“Poor accrual”
- withdrawn · 2025-10-14 · University of Rochester · Trastuzumab emtansine“Change in the landscape of current treatment of early stage breast cancer. Larger clinical trials answering similar questions are expected to result in the next few years.”
- withdrawn · 2025-10-03 · Karyopharm Therapeutics Inc · Polatuzumab Vedotin“Sponsor decision”
Paediatric incentives and obligations for TUBA1B's drugs
For vincristine, vinorelbine, ixabepilone, paclitaxel poliglumex, vinflunine, vinblastine, glembatumumab vedotin, mirvetuximab soravtansine, polatuzumab vedotin, cabazitaxel, trastuzumab emtansine, brentuximab vedotin: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · TUBA1B is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-000980-PIP01-10-M07 (Brentuximab vedotin, Treatment of anaplastic large cell lymphoma;Treatment of Hodgkin lymphoma): PM: decision on the application for modification of an agreed PIP, 28 Jan 2021; compliance positive 25 Jun 2021; EMEA-000980-PIP04-18 (Brentuximab vedotin, Treatment of Mature T and NK neoplasms (excluding anaplastic large-cell lymphoma and cutaneous Tcell lymphoma)): W: decision granting a waiver in all age groups for all conditions or indications, 8 Oct 2018; EMEA-002255-PIP01-17 (polatuzumab vedotin, Treatment of mature B-cell neoplasms): W: decision granting a waiver in all age groups for all conditions or indications, 11 Apr 2018; EMEA-001921-PIP01-16 (mirvetuximab soravtansine, Treatment of fallopian tube cancer;Treatment of ovarian carcinoma;Treatment of peritoneal carcinoma): W: decision granting a waiver in all age groups for all conditions or indications, 31 Jan 2017; +1 moreRule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA data download (dated snapshot), 2026-11-11
- EU orphan designation: yes · EU/3/26/3258 positive 28 Jul 2026: Treatment of ovarian cancer; EU/3/15/1458 positive 19 Mar 2015: Treatment of ovarian cancer; EU/3/11/939 withdrawn 11 Jan 2012: Treatment of cutaneous T-cell lymphoma; EU/3/08/596 withdrawn 15 Jan 2009: Treatment of Hodgkin's lymphoma; +2 moreRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Polivy: authorised since 16 Jan 2020, orphan medicine; Jevtana: authorised since 17 Mar 2011; Cabazitaxel Accord: authorised since 28 Aug 2020; Elahere: authorised since 14 Nov 2024, orphan medicine; +4 moreRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: yes · Vincristine Sulfate, date not given: Acute leukemia; MULTIPLE (in combination); Vinblastine sulfate, 25 Nov 1965: Palliative treatment of malignancies including generalized Hodgkin’s disease, histiocytosis X and testicular germ cell carcinoma; Brentuximab vedotin [Adcetris], 10 Nov 2022: Treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamideRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 764 interventional studies of vincristine, vinorelbine, ixabepilone, paclitaxel poliglumex, vinflunine, vinblastine, glembatumumab vedotin, mirvetuximab soravtansine, polatuzumab vedotin, cabazitaxel, trastuzumab emtansine, brentuximab vedotin include patients under 18; 190 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 85 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.